Research progress on the combination of PARP inhibitors and ferroptosis in ovarian cancer
WANG Xuening
NI Jing
YE Luxin
CHEN Yourong
ZHAO Qian
CHENG Xianzhong
CHEN Xiaoxiang
Abstract：Poly(ADP-ribose)polymerase inhibitors(PARPi)have inaugurated a new era of synthetic-lethal therapy for ovarian cancer;however,almost 50%of patients develop primary or acquired resistance during first-line or maintenance treatment,underscoring the need for additional synergistic targets.Ferroptosis—an iron-dependent,lipid-peroxidation-driven form of programmed cell death—has emerged as a promising complement.Recent studies show that PARPi weaken tumor antioxidant defenses and heighten oxidative stress,thereby lowering the ferroptotic threshold.In BRCA-wild-type or homologous-recombination-proficient ovarian-cancer models,combining PARPi with ferroptosis inducers markedly restores drug sensitivity and suppresses tumor growth.This review summarizes the molecular crosstalk between PARP inhibition and ferroptosis,highlights representative combination strategies,and discusses translational challenges,aiming to chart new avenues for overcoming PARPi resistance.
Keywords：ovarian cancerpoly(ADP-ribose)polymerase inhibitorsferroptosismechanisms of actioncombination therapy
Publication Date：2025-12-28
Online Publishing Date：2026-01-12(First online date of this platform, not the publication date of the document)
Pages：5( 1234-1238 )